About MPP The Medicines Patent Pool (MPP) is a United Nations-supported health organization committed to improving access to and development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP works with civil society, governments, international organizations, industry, patient groups and other stakeholders to prioritize and license the necessary medicines and pool intellectual property to promote generic manufacturing and the development of new formulations. To date, the MPP has signed agreements with eleven patent holders for thirteen antiretroviral DRUGS for HIV, an HIV technology platform, three direct-acting hepatitis C antivirals, tuberculosis treatment, long-acting technology, and two experimental oral antiviral treatments for COVID-19. MPP was founded by Unitaid, which remains MPP`s main funder. The MPP`s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC). The MPP`s COVID-19 activities are carried out with the financial support of the Japanese government and the SDC. For more information, medicinespatentpool.org/ and follow us on Twitter, LinkedIn and YouTube. Under the master license agreement between Pfizer and MPP, qualified generic manufacturers worldwide that receive sublicenses can supply PF-07321332 in combination with ritonavir in 95 countries, covering up to about 53% of the world`s population. This includes all low- and middle-income countries and some middle-income countries in sub-Saharan Africa, as well as countries that have transitioned from low- and middle-income status in the past five years. Pfizer will not receive royalties on sales in low-income countries and will continue to waive royalties on sales in all countries covered by the agreement, while COVID-19 continues to be classified by the World Health Organization as a public health emergency of international concern. “This license is so important because this oral drug, when approved or approved, is particularly well suited to low- and middle-income countries and could play a critical role in saving lives and contributing to global efforts to combat the current pandemic,” said Charles Gore, Executive Director of the MPP.
“PF-07321332 should be taken with ritonavir, an HIV drug that we know well because we have been licensed to do so for many years, and we will work with generic manufacturers to ensure there is enough care for COVID-19 and HIV.” The scope of patent protection is to grant an exclusive right to an invention, in this case a vaccine, for a limited period of time in order to exploit it and obtain economic benefits. In this way, the patent owner can prevent others from using their vaccine without permission – noting that the patent usually belongs to the inventor or, in many cases, the inventor`s employer. This dispute over the vaccine inventory could therefore mean that intellectual property rights to the vaccine may have to be shared between Moderna and the U.S. government. In such a case, if the three NIH scientists were finally recognized as co-inventors of the vaccine, the NIH would be considered co-owners and, as such, could grant licensing agreements without requiring Moderna`s approval. This, in turn, could have a significant impact on the global availability of the vaccine, especially in less developed regions. Pfizer has also begun and will continue to invest up to approximately $1 billion to support the manufacture and distribution of this test treatment candidate, including the exploration of potential contract manufacturing options. It has concluded advance purchase agreements with several countries and established bilateral contacts in about 100 countries around the world. The approval of Paxlovid, if approved, could make all the difference in the fight against Covid-19 and allow low- and middle-income countries with low vaccination rates to benefit from this generic and therefore save lives. The MPP will therefore sublicense sublicensees who have expressed interest in the manufacture and sale of the product.
More information on how to obtain an MPP license can be found here. Under the terms of the agreement between the two companies, qualified drug manufacturers that obtain sublicenses will be able to provide the investigational treatment in combination with ritonavir in 95 countries, including all low- and middle-income countries and some middle-income countries in sub-Saharan Africa (and countries that have moved from the bottom up to the center in the last 5 years). Pfizer announced the signing of a voluntary license agreement with the Medicines Patent Pool (MPP) for the pharmaceutical company`s oral antiviral drug candidate PF-07321332, administered in combination with low-dose ritonavir. The terms of the agreement authorize the MPP to facilitate the additional production and distribution of the investigational antiviral drug (subject to regulatory approval or approval) by sublicensing qualified generic manufacturers; The aim of this pact is to improve equitable access to treatments and vaccines in the world`s poorest regions. As mentioned earlier, Pfizer has signed an agreement to sublicense the production of the antiviral drug paxlovid. The license was granted to the Medicines Patent Pool (MPP), an international organization supported by the United Nations and founded by Unitaid whose mission is to improve developing countries` access to these medicines and advance their production. It is a way for pharmaceutical companies to license their life-saving treatments and facilitate the additional production and distribution of the generic compound, thus facilitating access worldwide. MPP is seeking Expressions of Interest (EoI) from potential sublicensees based worldwide for sublicenses to manufacture and sell the PF-07321332 co-pack; Ritonavir in the license area: The litigation is just beginning and for the moment the patent application has been filed, but the patent has not been granted. If the current dispute leads to a situation of co-ownership of the vaccine between Moderna and the NIH, additional licensing agreements could be signed that affect the availability and price of the vaccine. “This is the first license that allows the generic production of this drug. This is an important first step in ensuring that the latest COVID-19 tools are available in low- and middle-income countries, while being available in the richest countries,” said Hervé Verhoosel, spokesperson for Unitaid.
The voluntary licensing agreement for Pfizer`s COVID-19 oral antiviral treatment applicants will be administered with a low dose of ritonavir, an HIV drug, Unitaid said. “Unitaid, a global health authority, launched MPP ten years ago precisely for this purpose – to secure licenses that enable and accelerate access to affordable quality treatments for people in resource-limited environments,” said Dr Philippe Duneton, Executive Director of Unitaid. “During a pandemic, saving time is saving lives. This agreement could help us reach more people faster once the drug is approved and, combined with better access to testing, bring benefits to millions of people. NEW YORK & GENEVA–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) and the Medicines Patent Pool (MPP), a United Nations-backed healthcare organization committed to improving access to life-saving medicines for low- and middle-income countries, today announced the signing of a voluntary licensing agreement for Pfizer`s oral antiviral candidate for COVID-19 PF-07321332, which is used in combination with low-dose ritonavir (PF-07321332; Ritonavir) is administered. . . .
